Option Care Health, Inc.
As of Oct 22, 2026, Option Care Health is in Stage 1, the basing phase, now in week 12 (since Aug 5, 2026). It closed at $31.29, 14.5% below its 52-week high and above its 200-day average, which is falling.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is OPCH early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
OPCH among Medical Care Facilities23rd of 49 by relative strength
All 49 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AGL | Stage 3 · wk 8 | 98 | +6.8% |
| 2 | PACS | Stage 3 · wk 4 | 98 | +15.7% |
| 3 | LFST | Stage 2 · wk 24 | 97 | +4.0% |
| 4 | AMN | Stage 2 · wk 25 | 96 | +38.1% |
| 5 | NHC | Stage 2 · wk 59 | 95 | +8.4% |
| 6 | CON | Stage 2 · wk 22 | 94 | +14.9% |
| 7 | INNV | Stage 3 · wk 5 | 93 | +5.8% |
| 8 | MD | Stage 2 · wk 26 | 92 | +14.3% |
| …23 | OPCH | Stage 1 · wk 12 | 63 | +34.1% |
Option Care Health: quick answers
What stage is Option Care Health in?
As of Oct 22, 2026, Option Care Health (OPCH) is in Stage 1, the basing phase. It entered Stage 1 on Aug 5, 2026 and is in week 12. What the four stages mean
Is Option Care Health in an uptrend?
Not yet. Option Care Health is in Stage 1, a base that can come before an uptrend. It trades 18.6% above its 200-day average, which is falling.
How far is Option Care Health from its 52-week high?
Option Care Health closed at $31.29 on Oct 22, 2026, 14.5% below its 52-week high of $36.59. Its 52-week low is $19.52.
How has Option Care Health performed over the past year?
As of Oct 22, 2026, Option Care Health is up 10.9% over the past year and down 2.9% so far in 2026.
Which sector and industry is Option Care Health in?
Option Care Health is in the Medical Care Facilities industry, part of the Health Care sector.
About this companyHealth Care· Medical Care Facilities
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.